Table 1.
Summary of published cases of HLRCC-RCC and FH-deficient RCC treated with ICI and TKI combination
| RCC type | Treatment | N | Median duration of treatment (mo) | Best overall response, n (%) | ||||
|---|---|---|---|---|---|---|---|---|
| CR | PR | SD | PD | |||||
| Xu et al. [21] | FH-deficient RCC | ICI/TKI combination | 48 | 12 | 16 (33) | 25 (52) | 0 (0) | |
| Anti-PD1 + pazopanib | 5 | 12 | 2 (40) | 2 (40) | 1 (20) | |||
| Anti-PD1 + cabozantinib | 15 | 12 | 6 (40) | 8 (53) | 1 (6) | |||
| Anti-PD1 + lenvatinib | 4 | 9.5 | 2 (50) | 1 (25) | 1 (25) | |||
| Anti-PD1 + axitinib | 24 | 11 | 6 (25) | 14 (58) | 4 (17) | |||
| Bevacizumab + Erlotinib | 20 | 8 | 6 (30) | 9 (45) | 5 (25) | |||
| Srinivasan et al. [22] | HLRCC | Bevacizumab + Erlotinib | 43 | 19.3* | 2 (5) | 29 (67) | 12 (28) | 0 (0) |
ICI immunocheckpoint inhibitor, TKI tyrosine kinase inhibitor, PR partial response, CR complete response, SD stable disease, PD progressive
*Median duration of response (mo)